Advertisement

Topics

Latest "Summit Therapeutics SUMM Financial Strategic SWOT Analysis Review" News Stories

23:35 EDT 18th March 2019 | BioPortfolio

Here are the most relevant search results for "Summit Therapeutics SUMM Financial Strategic SWOT Analysis Review" found in our extensive news archives from over 250 global news sources.

More Information about Summit Therapeutics SUMM Financial Strategic SWOT Analysis Review on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Summit Therapeutics SUMM Financial Strategic SWOT Analysis Review for you to read. Along with our medical data and news we also list Summit Therapeutics SUMM Financial Strategic SWOT Analysis Review Clinical Trials, which are updated daily. BioPortfolio also has a large database of Summit Therapeutics SUMM Financial Strategic SWOT Analysis Review Companies for you to search.

Showing "Summit Therapeutics SUMM Financial Strategic SWOT Analysis Review" News Articles 1–25 of 31,000+

Monday 18th March 2019

CORRECTING and REPLACING Bioceres Crop Solutions Corp. Reports Financial Results for the Second Quarter and First Half Ended December 31, 2018

Please replace the first paragraph of the release with the following corrected version due to multiple revisions. The corrected release reads: BIOCERES CROP SOLUTIONS CORP. REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER AND FIRST HALF ENDED DECEMBER 31, 2018 On March 14, 2019, Bioceres LLC and Union Acquisition Corp. successful...


Cell composition analysis of bulk genomics using single-cell data

Scalable analysis of cell-type composition from single-cell transcriptomics using deep recurrent learning


Bioceres Crop Solutions Corp. Reports Financial Results for the Second Quarter and First Half Ended December 31, 2018

Following the consummation on March 14, 2019 of the previously announced business combination between Bioceres LLC and Union Acquisition Corp., Bioceres Crop Solutions Corp. (“Bioceres Crop Solutions”, the “Company”, “we”, “us” or “our”) (NYSE American: BIOX), a fully integrated provider of crop productivity solutions company, today announced ...

Latest REDUCE-IT Results Bolster Case For Amarin's Vascepa Fish Oil Pill

Data may pave way for inclusion in heart disease treatment guidelines, ACC spokesperson says.    

Tuesday’s national newspaper front pages | News UK Video News – Sky News

Tuesday's national newspaper front pages | News UK Video News Sky NewsConstitutional chaos after third vote on Brexit deal blocked The GuardianBrexit: Bercow chucks a hulking great spanner in the works BBC NewsThe Speaker has seized his Brexit moment – and now all bets are off The GuardianTheresa May's Brexit struggles have resolved nothing Financial TimesView full coverage on Google N...

DJO® Announces Presentation of Independent Clinical Study Using CMF™ Device

Spine Summit 2019 Presentation by Oregon Health & Science University Shows Patients Receiving Proprietary Combined Magnetic Field (CMF™) Treatment Experienced Significantly Improved Results DJO®, a leading global provider of medical technologies designed to get and keep people moving, announced today Oregon Health & Science University’s in...

Telix Pharmaceuticals Limited (TLX-AU): Updated PCa imaging guidelines de-risk lead asset

goetzpartners securities Limited 18-March-2019 / 20:05 GMT/BST Free to access research and investor meetings in a post-MiFID2 world. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail cli...

Aptar Pharma’s Bidose Nasal Drug Delivery Device Approved by U.S. FDA for Breakthrough Treatment of Depression

Aptar Pharma, a leading drug delivery systems provider, is pleased to announce that its Bidose nasal spray device was recently approved by the U.S. FDA for a breakthrough therapy in the field of depression. This marks the first FDA approval and U.S. launch of a prescription drug using Aptar Pharma’s patented Bidose nasal spray delivery system. This press ...

New Early Breast Cancer Drug to Reduce Risk of Recurrence or Death Approved for Australian Women(1)

NERLYNX® (neratinib) now approved by the Therapeutic Goods Administration for Australian women2 Leading Australian breast cancer oncologist says this is a 'huge step forward' for Australian women Five-year data shows NERLYNX reduces the risk of invasive disease recurrence or death by 42% in women with early-stage, HER2+/HR+ breast cancer3 NERLYNX now available to eligible women at ...

Polymeric Polyol Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Polymeric Polyol report provides an independent information about the Polymeric Polyol industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business overview and recent development.The rep...

Providing High Value, OTC Drugs Deserve Higher Profile In Health Care – CHPA

While Rx drug pricing is under attack by Congress, White House and consumer and public health advocacy groups, OTC drugs'...   

Halo Labs Continues to Expand Nevada Business

Halo Products Now Available in 21 of the State's 64 Dispensaries Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, Germany: A9KN) is pleased to provide a progress update on its Nevada business. The Company launched its first product offering in Nevada in the fall of 2018. Halo has primarily focused its activi...

Pure Biodiesel Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Pure Biodiesel report provides an independent information about the Pure Biodiesel industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business overview and recent development.The report ...

Patricia Hewitt on how the UK can learn from the healthcare system in India

Digitalisation in healthcare is needed just as much as it is in any other industry, according to Patricia Hewitt who argues the NHS long term plan should focus more on The post Patricia Hewitt on how the UK can learn from the healthcare system in India appeared first on Compelo Medical Devices - Latest industry news and analysis.

Paratek Pharma’s CFO Pagán to Leave for Job at an Early-Stage Biotech

Douglas Pagán, chief financial officer of Paratek Pharmaceuticals (NASDAQ: PRTK) since 2017, is resigning to take a role at an undisclosed early-stage biopharmaceutical company. The Boston company said Monday that Pagán’s last day will be April 5. He has entered into a consulting agreement through Dec. 23 to help with the transition of his responsibilities […]

Amgen’s Grauer Joins Corcept Therapeutics as Chief Medical Officer

Corcept Therapeutics (NASDAQ: CORT) has appointed Andreas Grauer to serve as chief medical officer. Grauer comes to Menlo Park, CA-based Corcept from Amgen (NASDAQ: AMGN), where he was vice president of global development. Corcept develops drugs that modulate a hormone called cortisol to treat metabolic and psychiatric disorders, as well as cancer. Corcept has already […]

Tilray, Inc. Reports Full Year 2018 Financial Results

Revenue Rises 110.0% to $43.1 (C$56.4) Million in 2018Strategic Partnerships and Acquisitions Position Tilray to Accelerate Global Sales Growth and Drive Long-Term Shareholder Value Tilray, Inc., (“Tilray” or the “Company”) (Nasdaq: TLRY) a global leader in cannabis research, cultivation, production and distribution, today report...

Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights

– Substantial revenue growth opportunity for Auryxia following robust 2018 commercial performance – – First regulatory submission for vadadustat expected in 2019 in Japan, following positive top-line results from pivotal phase 3 studies in Japanese subjects with anemia due to chronic kidney disease – – Multiple vadadustat phase ...

AZ’ Farxiga shows CV benefit in diabetes patients

New analysis of trial data highlight cardiovascular benefits of AstraZeneca’s diabetes drug Farxiga.

GW sells priority review voucher for $105m

GW Pharmaceuticals is selling its rare paediatric disease priority review voucher (PRV) for $105 million to Biohaven Pharmaceutical.

Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting

Oral Plenary Presentation Receives SGO Presidential Award Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that updated results from the cervical cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the efficacy of neratinib in HER2-mutated cancers, were reported at the Society of Gynecologic Oncology...

Nicox grants Ocumension certain Asian rights to Zerviate

Nicox SA licensed Ocumension Therapeutics exclusive rights to develop and commercialize the antihistamine Zerviate (cetirizin...

FDA Issues Update on Mortality Risk With Paclitaxel-Coated Products

MONDAY, March 18, 2019 -- A preliminary analysis has revealed a "potentially concerning signal" of increased long-term mortality risk with paclitaxel-coated products indicated for peripheral arterial disease (PAD), according to a March 15 update...

Active Interventions Generally Helpful for Urinary Incontinence

MONDAY, March 18, 2019 -- Most active interventions are more likely than no treatment to improve outcomes for women with either stress or urgency urinary incontinence (UI), according to a review published online March 19 in the Annals of Internal...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks